Hexvix (Hexaminolevulinate)

Hexvix is indicated for the optical diagnosis of non‑muscle invasive bladder cancer (NMIBC) during cystoscopic procedures.

• Enhances visualization of carcinoma in situ and papillary tumors under blue‑light cystoscopy.
• Assists urologists in mapping tumor extent before transurethral resection.
• Supports decision‑making for intravesical therapy by revealing residual or recurrent disease.
• May be used in surveillance cystoscopies to detect early recurrence.
• Provides complementary information to standard white‑light imaging.

• After intravesical administration, hexaminolevulinate is taken up preferentially by malignant urothelial cells, where intracellular enzymatic conversion yields protoporphyrin IX. This porphyrin accumulates in the cytoplasm and, when excited by blue light (approximately 400 nm), emits red fluorescence. The differential accumulation creates a contrast between cancerous and normal tissue, enabling real‑time visual identification of lesions during cystoscopy. The process relies on the higher metabolic activity and altered heme biosynthesis pathway of tumor cells.

Local and systemic adverse reactions have been reported following intravesical use of Hexvix; most are mild and transient, but rare serious events can occur.

Common

• Transient bladder irritation, including dysuria or urgency.
• Mild hematuria or urinary frequency.
• Flank or suprapubic discomfort during or shortly after instillation.
• Temporary photosensitivity of the bladder mucosa causing mild redness under blue light.

Serious

• Severe allergic reactions such as anaphylaxis.
• Persistent hematuria requiring medical evaluation.
• Acute urinary retention.
• Significant bladder wall inflammation (cystitis) with fever.

Before using Hexvix, clinicians should assess patient suitability and follow specific procedural guidelines to minimize risks.

• Confirm absence of active urinary tract infection prior to instillation.
• Avoid use in patients with known hypersensitivity to hexaminolevulinate or related porphyrins.
• Ensure complete bladder emptying after the procedure to reduce residual solution.
• Use protective eye and skin measures for staff handling the solution, as it is a photosensitizer.
• Monitor patients for signs of allergic reaction during and after administration.
• Do not use in pregnant or breastfeeding women unless benefits outweigh potential risks.

Hexvix may interact with other agents that affect porphyrin metabolism or photosensitivity; careful review of concomitant medications is recommended.

Avoid

• Concurrent use of systemic photosensitizing drugs (e.g., porfimer sodium, aminolevulinic acid) that could amplify fluorescence reactions.
• Strong CYP450 inducers that might alter intracellular conversion of hexaminolevulinate.

Use with caution

• Anticoagulants, because bladder irritation could increase bleeding risk.
• Immunosuppressive therapy, which may modify inflammatory response.
• Other intravesical agents administered within 24 hours, to prevent chemical incompatibility.